Try it now — load your own PDF or use the sample: ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...

I am selling my remaining shares in TARS for 90% gain. I am adding to my position in DERM on the dip back to $7. I am initiating a new position in REPL with 5% portfolio weighting. REPL- FDA's ...

Abstract: Unmanned aerial vehicles (UAVs) have found numerous applications and are expected to bring fertile business opportunities in the next decade. Among various enabling technologies for UAVs, ...

Replimune Group (REPL) has drawn attention after presenting updated clinical data from its IGNYTE phase 2 trial at the ESMO Congress 2025. The study combined RP1 with nivolumab in patients with acral ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...